A Phase II Study of PD 0332991 in Patients With Recurrent Rb Positive Glioblastoma.
Phase of Trial: Phase II
Latest Information Update: 22 Jul 2015
At a glance
- Drugs Palbociclib (Primary)
- Indications Glioblastoma; Gliosarcoma
- Focus Therapeutic Use
- 16 Jul 2015 Time frame of primary endpoint has changed from 6 months to up to 142 weeks.
- 11 Jun 2015 Status changed from completed to discontinued, as reported by ClinicalTrials.gov record.
- 21 May 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.